Short answer
UTAH MEDICAL PRODUCTS INC (UTMD) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $9M (down 12.1% year over year) with net income of $3M.
Q3 2026 key financials · XBRL
- Revenue
- $9M
- −12.1% YoY · +1.1% QoQ
- Net income
- $3M
- +5.9% YoY · +3.8% QoQ
- Operating margin
- 32.4%
- Gross margin
- 56.1%
- EPS (diluted)
- $0.88
- +7.3% YoY · +4.8% QoQ
Source: XBRL data from the UTAH MEDICAL PRODUCTS INC (UTMD) Q3 2026 10-Q on SEC EDGAR. USD.
UTAH MEDICAL PRODUCTS INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- 3Q revenue $8.621M, down 12.1% YoY from $9.812M, primarily lost PendoTECH and China distributor sales
- Operating margin 32.4% vs 26.6% YoY, gross margin 56.1% vs 57.1%
- Best category Blood Pressure Monitoring and Accessories $1.927M, up from $1.643M; worst Neonatal $1.667M, down from $2.176M
- Cash and investments $85.2M vs $85.8M year-end, with $3.0M dividends, $0.9M repurchases and $5.0M Orion acquisition
- 2026 revenue outlook down 7%-8%, EPS near $3.60 vs $3.48, with slower biopharma replacement sales and Filshie declines as headwinds
Risk Factors
- No material changes disclosed from the December 31, 2025 Form 10-K risk factors
- Unknown or currently immaterial risks could materially adversely affect business, financial condition, or operating results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other UTAH MEDICAL PRODUCTS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.